• 1
    Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-e304.
  • 2
    Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992;22:359-374.
  • 3
    Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
  • 4
    Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996;156:1677-1681.
  • 5
    Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-2568.
  • 6
    Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999;159:2029-2032.
  • 7
    Cheng S, Morrow DA, Sloan S, Antman EM, Sabatine MS. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation 2009;119:1195-1202.
  • 8
    Hassan WM, Flaker GC, Feutz C, Petroski GF, Smith D. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. J Thromb Thrombolysis 1995;2:245-249.
  • 9
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI;American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141S-159S.
  • 10
    White RH, Zhou H, Woo L, Mungall D. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements. Arch Intern Med 1997;157:2468-2472.
  • 11
    Rosborough TK. In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone. Pharmacotherapy 1998;18:1217-1223.
  • 12
    McLeay SC, Morrish GA, Kirkpatrick CM, Green B. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 2009;26:1626-1634.
  • 13
    Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005;44:1051-1065.
  • 14
    An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673-682.
  • 15
    Obesity: preventing and managing the global endemic. WHO Technical Report Series 894., 2000. Available at: at, accessed on April 1, 2010.
  • 16
    Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
  • 17
    Ertl AC, Diedrich A, Raj SR. Techniques used for the determination of blood volume. Am J Med Sci 2007;334:32-36.
  • 18
    Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977;56:605-612.
  • 19
    Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993;25:103-114.
  • 20
    Riney JN, Hollands JM, Smith JR, Deal EN. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother 2010;44:1141-1151.
  • 21
    Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis 2008;4:748-753.
  • 22
    Dee BM TM. Safety and efficacy of a high-intensity, weight-based, intravenous heparin protocol revision in patients who are obese. Hosp Pharm 2008;43:895-902.
  • 23
    Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 1993;119:874-881.
  • 24
    Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999;138:313-318.
  • 25
    Rosborough TK, Shepherd MF. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 2004;24:713-719.
  • 26
    Zimmermann AT, Jeffries WS, McElroy H, Horowitz JD. Utility of a weight-based heparin nomogram for patients with acute coronary syndromes. Intern Med J 2003;33:18-25.
  • 27
    Smith ML, Wheeler KE. Weight-based heparin protocol using antifactor Xa monitoring. Am J Health Syst Pharm 2010;67:371-374.
  • 28
    Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm 2001;58:2143-2146.
  • 29
    Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 1998;55:159-162.
  • 30
    Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989;8:65-68.
  • 31
    Holliday DM, Watling SM, Yanos J. Heparin dosing in the morbidly obese patient. Ann Pharmacother 1994;28:1110-1111.
  • 32
    Schwiesow SJ, Wessell AM, Steyer TE. Use of a modified dosing weight for heparin therapy in a morbidly obese patient. Ann Pharmacother 2005;39:753-756.
  • 33
    Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009;120:86-95.
  • 34
    Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005;5:291-305.
  • 35
    Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-393.
  • 36
    Lee MS, Wali AU, Menon V, et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002;14:91-101.
  • 37
    Badawi O. Possible effect of thyroid function on anticoagulant response to unfractionated heparin. Pharmacotherapy 2006;26:285-288.
  • 38
    Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
  • 39
    Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996;156:1645-1649.
  • 40
    Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy 1999;19:922-931.
  • 41
    Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006;96:547-552.